Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

Louis Navellier is a prominent American investor, author, and financial analyst, best known for his quantitative approach to ...

Central Coast nonprofits and companies are stepping up to support those impacted by the devastating Los Angeles County wildfires. Thousand Oaks-based biotech giant Amgen announced Jan. 14 that it and ...

Executives at Amgen made the case for MariTide’s differentiation, while Merck’s CEO contended that Keytruda’s coming loss of exclusivity can be managed. SAN FRANCISCO — For any hopes the dealmaking ...

Amgen is best known for its success in the biosimilar market. Image credit: Shutterstock / Michael Vi. Amgen has reported that its once-monthly dosing regimen and manufacturing capabilities will be ...

Amgen's strong product portfolio and pipeline developments, including, but not limited to, IMDELLTRA and MariTide, support a "Strong Buy" rating for long-term investors despite upcoming patent ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Amgen (NASDAQ:AMGN) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ...

To gain a panoramic view of Amgen's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year ...